Developing effective therapeutics for pain requires selecting endpoints that accurately reflect the biological, functional, and neurophysiological...
At this year’s Society for Neuroscience (SfN) meeting, our team presented a poster highlighting the advantages of using a porcine model to bridge the...
At the forefront of translational large-animal research, our team has developed clinically relevant pig models to study nerve injury and pain....
MD Biosciences has signed the Marseille Declaration, the first joint pharmaceutical industry statement on animal housing and use. By signing, we...
Spinal cord injury (SCI) remains one of the most challenging neurological conditions to treat, with few therapies successfully translating from the...
Bridging the gap between preclinical and clinical research remains one of the most pressing challenges in drug development. While early-stage studies...
MD Biosciences presented at the European Wound Management Association 2025 in Barcelona. Dr. Avital Schauder showcased groundbreaking research on...
At MD Biosciences, we are committed to ethical responsibility in animal welfare, ensuring the highest standards of care in preclinical research. As...
Neurological diseases often result in a combination of motor and cognitive deficits. To gain a broader understanding of the underlying biological...
